Scinopharm TaiwanTPE:1789 +0.73%76 Quick Ratio is 5.43 as of Dec. 2025, which is 11% below its 10-year median of 6.08. GuruFocus rates TPE:1789 with a GF Score™ of 76/100 and a GF Value™ of NT$27.02 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 994 Drug Manufacturers companies, Scinopharm Taiwan ranks better than 90.14% on this metric.
Scinopharm Taiwan has a quick ratio of 5.43. It generally indicates good short-term financial strength.
The historical rank and industry rank for Scinopharm Taiwan's Quick Ratio or its related term are showing as below:
TPE:1789'
s Quick Ratio Range Over the Past 10 Years
Min: 2.64 Med: 6.08 Max: 8.31
Current: 5.43
During the past 13 years, Scinopharm Taiwan's highest Quick Ratio was 8.31. The lowest was 2.64. And the median was 6.08.
TPE:1789's Quick Ratio is ranked better than 90.14% of 994
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs TPE:1789: 5.43
Scinopharm Taiwan (TPE:1789) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Scinopharm Taiwan Quick Ratio Related Terms
Scinopharm Taiwan Quick Ratio Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Scinopharm Taiwan's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan (TPE:1789) has a Quick Ratio of 5.43 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Scinopharm Taiwan and its competitors. This is 11% below median its historical median of 6.08. Over the past decade, Scinopharm Taiwan's Quick Ratio has ranged from 2.64 to 8.31. According to the industry distribution chart, Scinopharm Taiwan ranks #98 out of 994 companies in the Drug Manufacturers industry, placing it in the top 9.9%.
Is Scinopharm Taiwan's Quick Ratio too high?
Scinopharm Taiwan's current Quick Ratio of 5.43 is 11% below median its 10-year median of 6.08. Over the past 10 years, this metric has ranged from a low of 2.64 to a high of 8.31. The Drug Manufacturers industry median Quick Ratio is 1.45. Scinopharm Taiwan's value of 5.43 is 274.5% above this industry median. Based on the distribution chart, Scinopharm Taiwan ranks #98 out of 994 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #98 out of 994 companies for Quick Ratio. This places Scinopharm Taiwan in the top 10% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Scinopharm Taiwan's value of 5.43 is 274.5% above this benchmark. Historically, Scinopharm Taiwan's own Quick Ratio has ranged from 2.64 to 8.31 over the past decade. While the company's 10-year median is 6.08 vs. the industry median of 1.45, Scinopharm Taiwan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 994 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinopharm Taiwan's current Quick Ratio of 5.43 is 274.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current Quick Ratio is 5.43, which is 11% below median its own 10-year median of 6.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.02, compared to a current price of NT$20.65 — trading 23.6% below its estimated fair value. The current Quick Ratio is 5.43, which is 11% below median its 10-year median of 6.08 and 274.5% above the Drug Manufacturers industry median of 1.45. Scinopharm Taiwan's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Quick Ratio is 5.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$20.65 is trading 23.6% below its estimated GF Value™ of NT$27.02.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
Quick Ratio: 5.43 (11% below median its 10-year median of 6.08)
GF Value™: NT$27.02 vs. price of NT$20.65 (23.6% below fair value)
Industry Position: 274.5% above the Drug Manufacturers median (#98 of 994)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
76GF Score
Get the complete analysis for TPE:1789
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
